These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8235705)

  • 21. Donor lymphocyte infusion. An adaptive cellular immunotherapy for treatment of hematological malignancies.
    Owaidah TM
    Saudi Med J; 2003 Feb; 24(2):138-41. PubMed ID: 12682675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Late onset membranous nephropathy complicating donor lymphocyte infusion for leukaemia relapse after allogeneic stem cell transplantation.
    Lam MF; Au WY; Tse KC; Chan TM; Chan GS; Chan KW; Lai KN
    Am J Hematol; 2007 Apr; 82(4):327-8. PubMed ID: 17177190
    [No Abstract]   [Full Text] [Related]  

  • 23. Management of late CML relapse.
    Flowers M
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):847-8. PubMed ID: 18541206
    [No Abstract]   [Full Text] [Related]  

  • 24. Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation.
    Giralt S; O'Brien S; Talpaz M; Van Besien K; Chan KW; Rondón G; Andersson B; Mehra R; Khouri I; Estey E
    Cytokines Mol Ther; 1995 Jun; 1(2):115-22. PubMed ID: 9384668
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
    Saito T; Kanda Y; Kami M; Kato K; Shoji N; Kanai S; Ohnishi T; Kawano Y; Nakai K; Ogasawara T; Matsubara H; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S
    Clin Cancer Res; 2002 Apr; 8(4):1014-20. PubMed ID: 11948108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors.
    van Rhee F; Savage D; Blackwell J; Orchard K; Dazzi F; Lin F; Chase A; Bungey J; Cross NC; Apperley J; Szydlo R; Goldman JM
    Bone Marrow Transplant; 1998 May; 21(10):1055-61. PubMed ID: 9632281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Interferon-alpha in therapy of malignant hemoblastoses].
    Schuler M; Aulitzky WE; Schneller F; Peschel C; Huber C
    Internist (Berl); 1995 Dec; 36(12):1133-8. PubMed ID: 8567218
    [No Abstract]   [Full Text] [Related]  

  • 28. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
    Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
    Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leukemias and myeloma.
    Wiernik PH
    Cancer Chemother Biol Response Modif; 1996; 16():347-75. PubMed ID: 8639390
    [No Abstract]   [Full Text] [Related]  

  • 30. Acute severe form of lichenoid graft-versus-host disease after donor lymphocyte infusions.
    Ruiz-Genao DP; F-Peñas P; Daudén E; García-F-Villalta MJ; Fraga J; García-Diez A
    J Eur Acad Dermatol Venereol; 2006 May; 20(5):632-4. PubMed ID: 16684312
    [No Abstract]   [Full Text] [Related]  

  • 31. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia.
    Ruiz-Argüelles GJ; Gómez-Almaguer D; López-Martínez B; Cantú-Rodríguez OG; Jaime-Pérez JC; González-Llano O
    Haematologica; 2002 Aug; 87(8):894-6. PubMed ID: 12161373
    [No Abstract]   [Full Text] [Related]  

  • 32. [Changing concept of conventional therapy in chronic myelogenous leukemia].
    Ueda R
    Rinsho Ketsueki; 2000 Apr; 41(4):268-71. PubMed ID: 10846452
    [No Abstract]   [Full Text] [Related]  

  • 33. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.
    Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; Moreno-Lafont M; García-Latorre E; Ramírez-Sanjuan E; Montiel-Cervantes L; Tripp-Villanueva F; García-León LD; Ayala-Sánchez M; Rosas-Cabral A; Aviña-Zubieta JA; Galindo-Rodríguez G; Vadillo-Buenfil M; Salazar-Exaire D
    Ann Hematol; 2004 May; 83(5):295-301. PubMed ID: 15060749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different immune reconstitution in multiple myeloma, chronic myeloid leukemia and acute myeloid leukemia patients after allogeneic transplantation of peripheral blood stem cells.
    Rondelli D; Re F; Bandini G; Raspadori D; Arpinati M; Senese B; Stanzani M; Bonifazi F; Falcioni S; Chirumbolo G; Tura S
    Bone Marrow Transplant; 2000 Dec; 26(12):1325-31. PubMed ID: 11223973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dermatomyositis-like muscle pathology in patients with chronic graft-versus-host disease.
    Allen JA; Greenberg SA; Amato AA
    Muscle Nerve; 2009 Oct; 40(4):643-7. PubMed ID: 19670319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
    Klein JL; Avalos BR; Belt P; Taylor CA; Ezzone SA; Scholl MD; Fisher J; Young D; Copelan EA
    Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Leukemias and malignant lymphomas in children].
    Schmiegelow K
    Ugeskr Laeger; 1999 Apr; 161(15):2191-5. PubMed ID: 10222813
    [No Abstract]   [Full Text] [Related]  

  • 38. Adoptive cell-mediated immunotherapy with interleukin-2 (IL-2) for relapsing lymphoblastic crisis following mismatched unrelated bone marrow transplantation in a chronic myelogenous leukemia patient.
    Varadi G; Ackerstein A; Ben-Neriah S; Nagler A
    Bone Marrow Transplant; 1998 Jan; 21(1):93-6. PubMed ID: 9486502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hematopoietic stem cell transplantation in hematologic malignancy.
    Archuleta TD; Devetten MP; Armitage JO
    Panminerva Med; 2004 Mar; 46(1):61-74. PubMed ID: 15238882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage.
    Chaidos A; Kanfer E; Apperley JF
    Best Pract Res Clin Haematol; 2007 Jun; 20(2):125-54. PubMed ID: 17448953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.